Ethylone

hypertension, arrhythmia, structural heart disease, coronary artery disease

Ethylone's sympathomimetic activity via DAT and NET reuptake inhibition causes tachycardia and hypertension. Pre-existing hypertension, arrhythmias, structural heart disease, or history of myocardial infarction represent absolute contraindications. Myocardial infarction has been documented with other cathinone class agents.

epilepsy, seizure disorders

Seizures are a documented adverse effect of the synthetic cathinone class. Individuals with epilepsy or history of seizures are at elevated risk.

schizophrenia, schizoaffective disorder, psychotic disorders

Ethylone may precipitate acute psychosis, paranoid ideation, or hallucinations. Individuals with a personal or family history of psychotic disorders, schizophrenia, or schizoaffective disorder should avoid ethylone entirely.

bipolar I disorder, bipolar II disorder

Ethylone's combined monoamine reuptake inhibition and serotonin release may precipitate manic episodes in bipolar spectrum disorders.

pregnancy, breastfeeding

No reproductive toxicity data exist for ethylone or close structural analogs. Sympathomimetic cardiovascular effects and serotonergic disruption present theoretical risks. Classified as absolute contraindication by precautionary principle.

concurrent MAOI therapy

Concurrent use of any monoamine oxidase inhibitor with ethylone is absolutely contraindicated. This is among the most dangerous drug combinations in psychopharmacology.

SSRI therapy, SNRI therapy, tramadol use

Concurrent use of SSRIs, SNRIs, or tramadol with ethylone elevates serotonin syndrome risk. Tramadol carries additional risk due to dual SERT inhibition. Mechanism confirmed in vitro (Baldo 2018, Roulet et al. 2021).